[Anti-pulmonary fibrosis effect of acexamic acid in bleomycin therapy].
D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D001761:Bleomycin; C018802:6-acetylaminocaproic acid; D015119:Aminocaproic Acid
L'action antifibrosante pulmonaire de l'acide acéxamique dans les traitements à la bléomycine.